Related Experiment Video
Updated: Oct 4, 2025
11:52
Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
Published on: April 21, 2023
3.3K
Aminophenol-modified gold nanoparticles kill bacteria with minimal ototoxicity.
Le Wang1, Wenfu Zheng2, Leni Zhong1
1Shenzhen Key Laboratory of Smart Healthcare Engineering, Department of Biomedical Engineering, Southern University of Science and Technology, No. 1088 Xueyuan Rd, Nanshan District, Shenzhen, Guangdong 518055, P. R. China. jiang@sustech.edu.cn.
Chemical Communications (Cambridge, England)
|February 7, 2022
Summary
Aminophenol-modified gold nanoparticles show strong antibacterial effects against resistant bacteria and are less toxic than current treatments. These nanoparticles could offer a new clinical option for bacterial infections.
Area of Science:
- Nanotechnology
- Microbiology
- Pharmacology
Background:
- Multidrug-resistant bacteria pose a significant global health threat.
- Aminoglycosides are a class of antibiotics with known ototoxicity.
- Novel antibacterial agents with improved safety profiles are needed.
Purpose of the Study:
- To investigate the antibacterial efficacy of aminophenol-modified gold nanoparticles (AGNPs).
- To evaluate the ototoxicity of AGNPs compared to aminoglycosides.
- To assess the potential of AGNPs as alternative antibacterial agents.
Main Methods:
- Synthesis and characterization of aminophenol-modified gold nanoparticles (AGNPs).
- Assessment of antibacterial activity against multidrug-resistant bacteria using in vitro models.
- Evaluation of ototoxicity in relevant in vitro and in vivo models.
Main Results:
- AGNPs demonstrated potent antibacterial effects against a broad spectrum of multidrug-resistant bacteria.
- AGNPs exhibited significantly lower ototoxicity compared to traditional aminoglycoside antibiotics.
- In vitro and in vivo studies supported the safety and efficacy of AGNPs.
Conclusions:
- Aminophenol-modified gold nanoparticles are effective antibacterial agents.
- AGNPs present a less ototoxic alternative to aminoglycosides for treating bacterial infections.
- AGNPs hold promise for clinical applications as novel antibacterial therapeutics.
